1. Home
  2. UDMY vs KALV Comparison

UDMY vs KALV Comparison

Compare UDMY & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Udemy Inc.

UDMY

Udemy Inc.

HOLD

Current Price

$4.64

Market Cap

693.7M

Sector

Real Estate

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$17.00

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UDMY
KALV
Founded
2009
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
693.7M
757.7M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
UDMY
KALV
Price
$4.64
$17.00
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$9.00
$30.00
AVG Volume (30 Days)
1.5M
761.7K
Earning Date
04-29-2026
05-09-2026
Dividend Yield
N/A
N/A
EPS Growth
105.36
N/A
EPS
0.03
N/A
Revenue
$789,844,000.00
$50,000,000.00
Revenue This Year
$4.12
N/A
Revenue Next Year
$4.54
N/A
P/E Ratio
$158.17
N/A
Revenue Growth
0.42
495.66
52 Week Low
$4.35
$9.83
52 Week High
$8.92
$19.00

Technical Indicators

Market Signals
Indicator
UDMY
KALV
Relative Strength Index (RSI) 42.07 56.35
Support Level $4.35 $14.59
Resistance Level $5.38 $17.30
Average True Range (ATR) 0.22 1.10
MACD -0.02 -0.04
Stochastic Oscillator 14.94 57.48

Price Performance

Historical Comparison
UDMY
KALV

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Enterprise segment and Consumer segment, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America, and also has its presence in Europe, Middle East, Africa; Asia Pacific; and Latin America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: